1145 related articles for article (PubMed ID: 11654274)
21. Ethical issues in clinical neurological research.
Shore D; Berg K; Mullican C
J Calif Alliance Ment Ill; 1994; 5(1):61-2. PubMed ID: 11653329
[No Abstract] [Full Text] [Related]
22. Review panel cancels meeting as gene therapy proposals fall.
Wadman M
Nature; 1996 Feb; 379(6567):668. PubMed ID: 11644770
[No Abstract] [Full Text] [Related]
23. Gene therapy panel gets a thumbs up.
Science; 1995 Nov; 270(5240):1287. PubMed ID: 11644754
[No Abstract] [Full Text] [Related]
24. Exempt research: procedures in the intramural research program of the National Institutes of Health.
Wichman A; Mills D; Sandler AL
IRB; 1996; 18(2):3-5. PubMed ID: 11654755
[No Abstract] [Full Text] [Related]
25. IRB review of adverse events in investigational drug studies.
Prentice ED; Gordon B
IRB; 1997; 19(6):1-4. PubMed ID: 11656910
[No Abstract] [Full Text] [Related]
26. Human Gene Therapy Subcommittee: minutes of meeting, 29-30 Jul 1991.
U.S. National Institutes of Health. Recombinant DNA Advisory Committee. Human Gene Therapy Subcommittee
Hum Gene Ther; 1992 Aug; 3(4):439-55. PubMed ID: 11643020
[No Abstract] [Full Text] [Related]
27. A word to Varmus.
Pryor D; Hatfield M; Wyden R; Waxman HA
Hastings Cent Rep; 1996; 26(4):46-7. PubMed ID: 11644858
[No Abstract] [Full Text] [Related]
28. NIH panel proposes guidelines for human gene therapy research.
Med World News; 1984 Dec; 25(23):7. PubMed ID: 11645538
[No Abstract] [Full Text] [Related]
29. Ethical and legal considerations in dental caries research involving human subjects.
Branson R
J Dent Res; 1980 Jul; 59(Special Issue C):1214-364. PubMed ID: 11651755
[No Abstract] [Full Text] [Related]
30. Hospital failed on human research policy.
Science; 1998 Nov; 282(5391):1035. PubMed ID: 11645114
[No Abstract] [Full Text] [Related]
31. Informed consent process is deemed "legally and ethically invalid" by witness.
Maloney DM
Hum Res Rep; 1995 Jan; 10(1):4-5. PubMed ID: 11660008
[No Abstract] [Full Text] [Related]
32. IRBs and research with human biological materials.
Maloney DM
Hum Res Rep; 1999 Jan; 14(1):2. PubMed ID: 11657556
[No Abstract] [Full Text] [Related]
33. Regulatory orphans: juvenile prisoners as transvulnerable research subjects.
Reed JG
IRB; 1999; 21(2):9-14. PubMed ID: 11657875
[No Abstract] [Full Text] [Related]
34. Government guinea pigs.
Rothman DJ
N Y Times Web; 1994 Jan; ():E21. PubMed ID: 11646304
[No Abstract] [Full Text] [Related]
35. Annual review: observed deficiencies and suggested corrections.
Adams MS; Conrad DA
IRB; 1996; 18(6):1-4. PubMed ID: 11654743
[No Abstract] [Full Text] [Related]
36. An overview of FDA, IRBs and regulations.
Petricciani JC
IRB; 1981 Dec; 3(10):1-3, 11. PubMed ID: 11649413
[No Abstract] [Full Text] [Related]
37. Human experimentation: the review process in practice.
Cowan DH
Case West Reserve Law Rev; 1975; 25(3):533-64. PubMed ID: 11661165
[No Abstract] [Full Text] [Related]
38. The FDA's enforcement of IRBs and patient informed consent.
Kelsey FO
Food Drug Cosmet Law J; 1989 Jan; 44(1):13-20. PubMed ID: 11651627
[No Abstract] [Full Text] [Related]
39. Much more research to fall under IRB review.
Maloney DM
Hum Res Rep; 1999 Jul; 14(7):3. PubMed ID: 11658059
[No Abstract] [Full Text] [Related]
40. Toward a more comprehensive approach to protecting human subjects: the interface of data safety monitoring boards and institutional review boards in randomized clinical trials.
Gordon VM; Sugarman J; Kass N
IRB; 1998; 20(1):1-5. PubMed ID: 11655324
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
